Delgocitinib;1263774-59-9
=
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Number: D090000
English Name: Delgocitinib
English Alias: 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile
CAS Number: 1263774-59-9
Molecular Formula: C16H18N6O
Molecular Weight: 310.35
Product Advantages: Delgocitinib is a highly selective JAK inhibitor with strong affinity and inhibitory activity towards JAK family kinases, which can precisely block the relevant intracellular inflammatory signaling pathways. With a stable chemical structure, it exhibits excellent pharmacokinetic properties in both in vitro and in vivo experiments. It is rapidly absorbed orally, has high bioavailability, and a reasonable plasma protein binding rate. It also features good safety and tolerability, effectively reducing interference with other non-targeted signaling pathways and minimizing the risk of adverse reactions.
Application Fields:
Dermatological Disease Treatment: Mainly used for treating inflammatory skin diseases such as psoriasis and atopic dermatitis. By inhibiting the JAK signaling pathway, it reduces the production and release of inflammatory cytokines, alleviates skin inflammatory reactions, and relieves symptoms such as skin itching, erythema, and scaling.
Autoimmune Disease Research: In the research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, it serves as a potential therapeutic drug to evaluate its regulatory effect on the immune system and clinical treatment efficacy.
Drug Development: As a tool compound, it is used to study the role of the JAK signaling pathway in the occurrence and development of diseases, facilitating the development of new targeted drugs. It can also be used to optimize pharmaceutical formulation processes to improve drug stability and bioavailability.
Background Description: The Janus kinase (JAK) - signal transducer and activator of transcription (STAT) signaling pathway plays a crucial role in cytokine - mediated immune and inflammatory responses. The abnormal activation of this pathway is closely related to the occurrence and development of various inflammatory and autoimmune diseases. The development of Delgocitinib is based on in - depth research on the JAK - STAT signaling pathway, aiming to achieve targeted treatment of related diseases by selectively inhibiting JAK kinase activity, providing safer and more effective treatment options for patients.
Research Status:
Clinical Research: Multiple clinical trials have shown that Delgocitinib exhibits good efficacy in the treatment of psoriasis and atopic dermatitis, significantly improving patients' skin symptoms and quality of life. Currently, further exploration is underway to determine the optimal dosage, treatment course, and combination therapy regimens with other drugs, while also evaluating its safety and tolerability during long - term use.
Mechanism of Action Research: Through molecular and cellular biology techniques, researchers are deeply studying the binding mode of Delgocitinib with JAK kinases and its inhibitory effect on the phosphorylation of downstream STAT proteins, clarifying its specific mechanisms in the regulation of immune cell differentiation, proliferation, and inflammatory cytokine expression, providing a theoretical basis for optimizing drug design.
Drug Resistance Research: With the advancement of clinical applications, drug resistance may occur in some patients. Current research focuses on exploring the mechanisms of drug resistance, such as mutations in JAK kinases and the activation of bypass signaling pathways, aiming to develop strategies to overcome resistance and improve the long - term therapeutic effects of the drug.
New Indication Expansion: Active research is being conducted on the application of Delgocitinib in other inflammatory and autoimmune diseases (such as alopecia areata, inflammatory bowel disease), evaluating its therapeutic potential and expanding the scope of drug application.
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
